S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Heska (HSKA) Stock Forecast, Price & News

+5.04 (+5.25%)
(As of 05/27/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
71,909 shs
Average Volume
75,126 shs
Market Capitalization
$1.09 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive HSKA News and Ratings via Email

Sign-up to receive the latest news and ratings for Heska and its competitors with MarketBeat's FREE daily newsletter.

Heska logo

About Heska

Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; and turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force, and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was founded in 1988 and is based in Loveland, Colorado.


Heska (NASDAQ:HSKA) PT Lowered to $150.00
See More Headlines

Industry, Sector and Symbol

Diagnostic substances
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$253.74 million
Cash Flow
$1.05 per share
Book Value
$39.72 per share


Net Income
$-1.15 million
Pretax Margin




Free Float
Market Cap
$1.09 billion
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.40 out of 5 stars

Medical Sector

196th out of 1,424 stocks

Diagnostic Substances Industry

2nd out of 27 stocks

Analyst Opinion: 3.4Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -

Heska (NASDAQ:HSKA) Frequently Asked Questions

Is Heska a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Heska in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Heska stock.
View analyst ratings for Heska
or view top-rated stocks.

When is Heska's next earnings date?

Heska is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Heska

How were Heska's earnings last quarter?

Heska Co. (NASDAQ:HSKA) posted its quarterly earnings data on Monday, May, 9th. The medical research company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by $0.30. The medical research company had revenue of $64.80 million for the quarter, compared to analyst estimates of $66.32 million. Heska had a negative net margin of 5.04% and a negative trailing twelve-month return on equity of 0.95%. The company's revenue was up 7.1% compared to the same quarter last year. During the same period last year, the company posted $0.20 earnings per share.
View Heska's earnings history

What guidance has Heska issued on next quarter's earnings?

Heska updated its FY 2024 earnings guidance on Wednesday, May, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $380.00 million-$400.00 million.

What price target have analysts set for HSKA?

4 analysts have issued 1 year target prices for Heska's shares. Their forecasts range from $155.00 to $280.00. On average, they expect Heska's stock price to reach $205.20 in the next twelve months. This suggests a possible upside of 103.1% from the stock's current price.
View analysts' price targets for Heska
or view top-rated stocks among Wall Street analysts.

Who are Heska's key executives?
Heska's management team includes the following people:
  • Mr. Kevin S. Wilson, CEO, Pres & Director (Age 50, Pay $1.84M) (LinkedIn Profile)
  • Ms. Catherine I. Grassman CPA, Exec. VP & CFO (Age 46, Pay $583.3k) (LinkedIn Profile)
  • Dr. Nancy Wisnewski, Exec. VP & COO (Age 59, Pay $581.23k)
  • Mr. Christopher D. Sveen, EVP, Chief Admn. Officer, Gen. Counsel, Corp. Sec. & Pres of Diamond Animal Health (Age 39, Pay $536.41k)
  • Mr. Steven M. Eyl, Exec. VP, Chief Commercial Officer & Pres of scil animal care company (Age 56, Pay $587.63k)
  • Mr. Jon Aagaard, Director of Investor Relations
  • Mr. Anthony C. Providenti Jr., Exec. VP of Corp. Devel. (Age 55)
  • Ms. Eleanor F. Baker, Exec. VP, MD & COO of scil animal care company (Age 37)
  • Daniel J. Pollack, VP of Imaging Operations, Treasurer & Assistant Sec.
  • Laurie E. Peterson, VP of Heska Des Moines
What is Kevin S. Wilson's approval rating as Heska's CEO?

5 employees have rated Heska CEO Kevin S. Wilson on Glassdoor.com. Kevin S. Wilson has an approval rating of 57% among Heska's employees. This puts Kevin S. Wilson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Heska own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Gilead Sciences (GILD), Exxon Mobil (XOM), Netflix (NFLX), Biogen (BIIB), AbbVie (ABBV), Amgen (AMGN), Broadcom (AVGO), Alibaba Group (BABA), Exelixis (EXEL) and Merck & Co., Inc. (MRK).

What is Heska's stock symbol?

Heska trades on the NASDAQ under the ticker symbol "HSKA."

Who are Heska's major shareholders?

Heska's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (17.14%), Nine Ten Capital Management LLC (7.76%), Vanguard Group Inc. (6.56%), State Street Corp (3.37%), Riverbridge Partners LLC (3.12%) and abrdn plc (3.07%). Company insiders that own Heska stock include Bonnie J Trowbridge, Catherine Grassman, Jason D Aroesty, Kevin S Wilson, Nancy Wisnewski and Sharon J Larson.
View institutional ownership trends for Heska

Which major investors are selling Heska stock?

HSKA stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., G2 Investment Partners Management LLC, SG Capital Management LLC, First Trust Advisors LP, Motley Fool Asset Management LLC, Thornburg Investment Management Inc., Invesco Ltd., and Handelsbanken Fonder AB. Company insiders that have sold Heska company stock in the last year include Catherine Grassman, Nancy Wisnewski, and Sharon J Larson.
View insider buying and selling activity for Heska
or view top insider-selling stocks.

Which major investors are buying Heska stock?

HSKA stock was acquired by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Nine Ten Capital Management LLC, Riverbridge Partners LLC, Grandeur Peak Global Advisors LLC, Vanguard Group Inc., BlackRock Inc., Walleye Capital LLC, and Walleye Capital LLC.
View insider buying and selling activity for Heska
or or view top insider-buying stocks.

How do I buy shares of Heska?

Shares of HSKA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Heska's stock price today?

One share of HSKA stock can currently be purchased for approximately $101.03.

How much money does Heska make?

Heska has a market capitalization of $1.09 billion and generates $253.74 million in revenue each year. The medical research company earns $-1.15 million in net income (profit) each year or ($1.27) on an earnings per share basis.

How many employees does Heska have?

Heska employs 655 workers across the globe.

What is Heska's official website?

The official website for Heska is www.heska.com.

How can I contact Heska?

Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The medical research company can be reached via phone at (970) 493-7272, via email at [email protected], or via fax at 970-619-3003.

This page was last updated on 5/29/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.